JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 3,625 articles

Articles by James Calloway

Bradesco Shares Rise as Q2 Target Looms; Earnings Outlook Tightens
Earnings

Bradesco Shares Rise as Q2 Target Looms; Earnings Outlook Tightens

Bradesco shares gained 1.8% as the bank faces a tighter path to its 2026 earnings target, requiring average post-provision NII of R$10.54 billion in the next three quarters.

Wabtec Surges 11% as Order Backlog Swells, Driving Higher Valuation
Earnings

Wabtec Surges 11% as Order Backlog Swells, Driving Higher Valuation

Wabtec shares jumped 10.7% to $291.68 after Q2 results beat estimates and total backlog surged 41.7% to $30.93 billion, driving a 7.6% expansion in the forward P/E multiple.

WAB
Pegasystems Shares Plunge 16% on AI-Led Slowdown and ACV Growth Concerns
Earnings

Pegasystems Shares Plunge 16% on AI-Led Slowdown and ACV Growth Concerns

Pegasystems (NASDAQ:PEGA) shares dropped 16% after ACV growth slowed sharply, making the February 2026 target seem out of reach due to AI uncertainty and buyer hesitation.

PEGA APPN NOW CRM
Ford Stock Gains as Market Shifts Focus from Volume to Profit Quality
Earnings

Ford Stock Gains as Market Shifts Focus from Volume to Profit Quality

Ford shares climbed 1.4% to $14.47, surpassing FactSet's median price target, as investors shift focus from sales volume to profit quality ahead of Q2 earnings.

F GM
ServiceNow Stock Slips on Q2 Backlog Concerns Despite Revenue Growth
Earnings

ServiceNow Stock Slips on Q2 Backlog Concerns Despite Revenue Growth

ServiceNow shares declined 4.9% after Q2 backlog data disappointed, despite a revenue uptick. Investors await earnings, with focus on organic growth and AI impact.

NOW CRM WDAY ORCL
Netflix Stock Gains on Record Buyback, Revenue Deceleration Raises Questions
Earnings

Netflix Stock Gains on Record Buyback, Revenue Deceleration Raises Questions

Netflix shares climbed 2.2% on a record $4.7 billion buyback, but slowing revenue growth and a weaker Q3 forecast keep investors cautious.

NFLX DIS CMCSA
AMC Shares Rise Despite Dilution Outpacing EBITDA Growth
Earnings

AMC Shares Rise Despite Dilution Outpacing EBITDA Growth

AMC shares climbed 7.5% early Wednesday, but the company's adjusted diluted share count expanded faster than its adjusted EBITDA growth, causing per-share metrics to decline.

AMC CNK IMAX
Philip Morris Shares Dip Despite Q2 Beat as Q3 Outlook Disappoints
Earnings

Philip Morris Shares Dip Despite Q2 Beat as Q3 Outlook Disappoints

Philip Morris reported Q2 adjusted EPS of $2.20, beating estimates, but Q3 guidance midpoint is 8.1% below consensus, sending shares down 1.8%.

PM BTI
Super Micro Soars on Margin Reset, Sending AI Hardware Stocks Mixed
Earnings

Super Micro Soars on Margin Reset, Sending AI Hardware Stocks Mixed

Super Micro Computer shares surged 12.6% after raising its gross margin forecast, implying a $847 million increase in gross profit and sparking mixed moves in AI hardware stocks.

SMCI GOOGL HPE NVDA AMD SOXX JPM
American Airlines Sees Record Q2 Revenue, Profit Nearly Flat
Earnings

American Airlines Sees Record Q2 Revenue, Profit Nearly Flat

American Airlines projects record Q2 revenue of $16.7B but EPS of only $0.03-$0.05, highlighting margin challenges from fuel costs and competition.

AAL UAL DAL ALK
GE Vernova Boosts Cash Flow Forecast by $5B; Shares Slide on Quality Concerns
Earnings

GE Vernova Boosts Cash Flow Forecast by $5B; Shares Slide on Quality Concerns

GE Vernova lifted its 2026 free cash flow midpoint by $5B, yet shares reversed gains as analysts questioned the cash quality. Strong order growth of 88% was overshadowed.

GEV PWR
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Earnings

Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset

Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.

DHR TMO